DK1885746T3 - Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs) - Google Patents

Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs)

Info

Publication number
DK1885746T3
DK1885746T3 DK06734527.2T DK06734527T DK1885746T3 DK 1885746 T3 DK1885746 T3 DK 1885746T3 DK 06734527 T DK06734527 T DK 06734527T DK 1885746 T3 DK1885746 T3 DK 1885746T3
Authority
DK
Denmark
Prior art keywords
soluble
protein coupled
coupled receptors
sgpcrs
compositions related
Prior art date
Application number
DK06734527.2T
Other languages
Danish (da)
English (en)
Inventor
Alon Chen
Marilyn Perrin
Wylie Vale
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of DK1885746T3 publication Critical patent/DK1885746T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
DK06734527.2T 2005-02-08 2006-02-08 Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs) DK1885746T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65086605P 2005-02-08 2005-02-08
PCT/US2006/004321 WO2006086402A2 (en) 2005-02-08 2006-02-08 Compositions and methods related to soluble g-protein coupled receptors(sgpcrs)

Publications (1)

Publication Number Publication Date
DK1885746T3 true DK1885746T3 (da) 2012-03-26

Family

ID=36793648

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06734527.2T DK1885746T3 (da) 2005-02-08 2006-02-08 Sammensætninger relateret til opløselige G-protein-koblede receptorer (sGPCRs)

Country Status (11)

Country Link
US (2) US7507794B2 (enExample)
EP (1) EP1885746B1 (enExample)
JP (1) JP4859248B2 (enExample)
KR (1) KR20070112155A (enExample)
CN (1) CN101137668B (enExample)
AT (1) ATE540970T1 (enExample)
AU (1) AU2006212813B2 (enExample)
CA (1) CA2597065C (enExample)
DK (1) DK1885746T3 (enExample)
RU (1) RU2423378C2 (enExample)
WO (1) WO2006086402A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
AU2008303893A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
US20100286029A1 (en) * 2007-09-11 2010-11-11 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
WO2009043469A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of pneumadin as a therapeutic agent
EP2470560B1 (en) 2009-08-28 2015-06-10 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2011062935A1 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of California Compositions and assay systems for intracellular processes
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
KR101963914B1 (ko) * 2011-02-23 2019-03-29 매사추세츠 인스티튜트 오브 테크놀로지 수용성 막 단백질 및 이의 제조 방법 및 이의 사용 방법
JP6562632B2 (ja) * 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
US10995361B2 (en) 2017-01-23 2021-05-04 Massachusetts Institute Of Technology Multiplexed signal amplified FISH via splinted ligation amplification and sequencing
WO2018157048A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for examining podocyte foot processes in human renal samples using conventional optical microscopy
WO2018157074A1 (en) 2017-02-24 2018-08-30 Massachusetts Institute Of Technology Methods for diagnosing neoplastic lesions
US11180804B2 (en) 2017-07-25 2021-11-23 Massachusetts Institute Of Technology In situ ATAC sequencing
WO2019046699A1 (en) * 2017-09-01 2019-03-07 Massachustetts Institute Of Technology NON-DETERGENT GPCR BIOELECTRONIC INTERFACES COUPLED TO THE 2D S-PROTEIN NETWORK, DEVICES AND METHODS OF USE THEREOF
US11173992B2 (en) 2017-12-28 2021-11-16 Legionarus, Llc Buoyancy garment
WO2019156957A1 (en) 2018-02-06 2019-08-15 Massachusetts Institute Of Technology Swellable and structurally homogenous hydrogels and methods of use thereof
WO2020013833A1 (en) 2018-07-13 2020-01-16 Massachusetts Institute Of Technology Dimethylacrylamide (dmaa) hydrogel for expansion microscopy (exm)
US11471112B2 (en) 2018-11-21 2022-10-18 Legionarius, Llc Mobile application for wearable device
USD905935S1 (en) 2019-02-20 2020-12-29 Legionarius, Llc Shirt with back pocket
US12478324B2 (en) 2019-02-20 2025-11-25 Legionarius, Llc Sensors for wearable devices
US12405193B2 (en) 2019-02-22 2025-09-02 Massachusetts Institute Of Technology Iterative direct expansion microscopy
US12265004B2 (en) 2019-11-05 2025-04-01 Massachusetts Institute Of Technology Membrane probes for expansion microscopy
US11802822B2 (en) 2019-12-05 2023-10-31 Massachusetts Institute Of Technology Multiplexed expansion (MultiExM) pathology
WO2026021448A1 (zh) * 2024-07-22 2026-01-29 健达九州(北京)生物科技有限公司 一种M4Di变体以及其治疗癫痫的应用
CN121177454B (zh) * 2025-09-05 2026-07-14 南通大学 Gip受体激动剂在促进毛发再生中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
KR20020092891A (ko) * 1999-07-15 2002-12-12 리서치 디벨럽먼트 파운데이션 코르티코트로핀 분비 인자 수용체 2 결핍 마우스 및 이의용도
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
WO2006031322A2 (en) 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis

Also Published As

Publication number Publication date
WO2006086402A3 (en) 2006-12-14
CA2597065A1 (en) 2006-08-17
RU2007133648A (ru) 2009-03-20
ATE540970T1 (de) 2012-01-15
RU2423378C2 (ru) 2011-07-10
US20090117649A1 (en) 2009-05-07
CN101137668B (zh) 2011-08-17
KR20070112155A (ko) 2007-11-22
EP1885746B1 (en) 2012-01-11
CA2597065C (en) 2014-10-14
EP1885746A2 (en) 2008-02-13
AU2006212813A1 (en) 2006-08-17
WO2006086402A2 (en) 2006-08-17
US8258279B2 (en) 2012-09-04
JP4859248B2 (ja) 2012-01-25
CN101137668A (zh) 2008-03-05
US7507794B2 (en) 2009-03-24
US20070042954A1 (en) 2007-02-22
JP2008529500A (ja) 2008-08-07
AU2006212813B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
ATE540970T1 (de) Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
EA021242B9 (ru) Антитела к остеопротегерин лиганду (опгл)
SG166090A1 (en) Il-13 binding agents
MX358705B (es) Agentes de union de esclerostina.
NO20071790L (no) Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
MEP35408A (en) Tweak binding antibodies
PL2320940T3 (pl) Przeciwciała ludzkie, które wiążą gen aktywacji limfocytów-3 (LAG-3), oraz ich zastosowania
DK1740616T3 (da) Anti-TFR-antistof
NO20074740L (no) Fremgangsmater for anvendelse av dodsreseptoragonister og EGFR-inhibitorer
EA200870465A1 (ru) Антагонисты рецептора il-8
NO20081298L (no) Peptider og forbindelser som binder til en reseptor
NO20080766L (no) IL-6-bindendende proteiner
DK1755634T3 (da) Oligopeptider til formindskelse af forhöjet blodurinstofkoncentration
MX341064B (es) Variantes de la familia il-1.
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EA200600477A1 (ru) Пептиды и соединения, которые связываются с рецептором
CY1111486T1 (el) Μιμητικα αντισωματα (mimetibodies) δεσμευμενα με υποδοχεα μελανοκορτινης, συνθεσεις, μεθοδοι και χρησεις
ATE550354T1 (de) Humane ringspezifische bnp-antikörper
DK1809123T3 (da) Dimensionsstabilt foder til selskabsdyr med lavt indhold af carbohydrat
ATE507817T1 (de) Partikel
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
EA200702193A1 (ru) Гликозилирование белков